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S U M M A R Y
Objective: To compare responses to tenofovir (TDF) and entecavir (ETV) therapy.
Methods: This was a multicenter retrospective study including treatment-naı¨ve patients with chronic
hepatitis B (CHB) who received TDF or ETV. The primary end-points were undetectable HBV-DNA at
48 weeks and serological and biochemical responses.
Results: Out of 195 CHB patients, 90 (46%) received TDF and 105 (54%) received ETV; 72% were male,
their mean age was 43  12 years, and the mean duration of treatment was 30.2  15.7 months. Hepatitis B
e antigen (HBeAg) seropositivity was 32% in the TDF group and 34% in the ETV group. HBeAg seroconversion
rates in HBeAg-positive patients were 24% in the TDF group and 39% in the ETV group; the difference was not
signiﬁcant (p = 0.2). The mean time to alanine aminotransferase (ALT) normalization and rates of ALT
normalization at 3, 6, 12, 18, and 24 months were similar in the two groups (p > 0.05). The mean time to
undetectable HBV-DNA levels in the TDF and ETV groups was 11.5  8.9 and 12.9  10.8 months,
respectively (p = 0.32). A signiﬁcantly greater decline in HBV-DNA levels at 12 and 18 months was observed
in the TDF group (p = 0.02 and p = 0.03, respectively). Seven (7%) patients on ETV therapy had virological
breakthrough (p = 0.01). Only one patient in each group had hepatitis B surface antigen (HBsAg) clearance.
None of the patients developed decompensation or hepatocellular carcinoma during treatment.
Conclusions: The two drugs appear to have similar efﬁcacy in CHB patients. However, 7% of patients on
ETV therapy had virological breakthrough, while none of the patients on TDF therapy did.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Chronic hepatitis B (CHB) is a signiﬁcant health problem
worldwide that may cause serious complications such as cirrhosis,
liver failure, and/or hepatocellular carcinoma (HCC). Nearly
400 million people are estimated to be infected chronically with
hepatitis B virus (HBV). Five-year cumulative probabilities for§ This study was presented as an e-poster at APASL 2014, Brisbane, Australia.
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http://dx.doi.org/10.1016/j.ijid.2014.09.004
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).developing hepatic decompensation and cirrhosis are reported to
be 20% and 8–20%, respectively.1 Turkey has an intermediate
endemicity for CHB (approximately 5%).
To date, sustained virological suppression to prevent HBV-
related mortality has been the only achievable goal in the therapy
of CHB, since rates of hepatitis B surface antigen (HBsAg)
seroclearance (i.e., ‘complete cure’) remain very low.2,3
Two categories of therapeutic agents are currently available for
the treatment of CHB: (1) immunomodulatory agents (interferon-
alpha and pegylated interferon-alpha), and (2) oral nucleos(t)ide
analogues (NAs) (lamivudine, adefovir, telbivudine, entecavir, and
tenofovir). The response rate to interferons remains low, particularlyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Turkey.4,5 Furthermore, interferon tolerability is poor due to
signiﬁcant adverse effects.6 The mechanism of action of NAs is
the inhibition of HBV-DNA polymerase activity and therefore the
suppression of HBV replication. Rates of resistance to lamivudine
and adefovir have been reported to be 65–70% and 18–29% after 4–5
years of treatment.7,8 Telbivudine caused a resistance rate of 5–25%
in hepatitis B e antigen (HBeAg)-positive patients and 2.3–11% in
HBeAg-negative patients.9
Entecavir (ETV; approved in 2005) and tenofovir disoproxil
fumarate (TDF; approved in 2008) are NAs with high potency for
profound and durable viral suppression and genetic barriers
against resistance; these drugs are recommended for the ﬁrst-line
treatment of CHB in current guidelines.1,10–12 The long-term use of
these agents has resulted in no or very low resistance to date.13,14
Although the efﬁcacy of each has been assessed in various large-
scale studies, real-life data on the comparative long-term efﬁcacy
of these drugs are very limited in the literature. Moreover, the
numbers of eligible patients included in the few previously
published studies directly comparing the two drugs have been
quite small (patients on TDF and ETV therapy, respectively: Ceylan
et al.,15 66 and 51 patients; Dogan et al.,16 65 and 29 patients;
Guzelbulut et al.,17 20 and 24).
The aim of this retrospective study of real-life practice was to
compare the cumulative virological, serological, and biochemical
responses to TDF and ETV in a large group of HBeAg-positive and
negative treatment-naı¨ve patients with a high viral load, over the
long-term.
2. Materials and methods
2.1. Study design and data collection
In this retrospective real-life study conducted at four centres
(two universities, one tertiary education and research centre, and
one state hospital in Turkey), treatment-naı¨ve CHB patients with a
high viral load (>2  106 IU/ml), who received TDF (245 mg/day)
or ETV (0.5 mg/day) in a compliant manner between January
2008 and October 2013, were included. The primary end-points
were undetectable serum HBV-DNA levels at 48 weeks (virological
response) and serological (HBeAg seroclearance/conversion in
HBeAg-positive cases) and biochemical (alanine aminotransferase
(ALT) normalization) responses; secondary end-points were
persistence of detectable HBV-DNA and virological breakthrough.
Inclusion criteria were the following: (1) HBsAg seropositivity.
(2) Pre-treatment liver biopsy consistent with CHB. (3) Pre-
treatment serum HBV-DNA levels >2  106 IU/ml in both HBeAg-
positive and HBeAg-negative patients. (The prescription of ETV and
TDF is restricted to these patients alone by the National
Reimbursement Policy regulated by the Ministry of Health in
Turkey.) (4) Positive or negative serology for HBeAg. (5) Serum
HBV-DNA levels measured at 3–6-month intervals by PCR. (6) No
prior history of receiving any treatment for CHB. (7) ETV (0.5 mg/
day) or TDF (245 mg/day; the form available in Turkey) therapy for
at least 1 year.
Exclusion criteria were the following: Previous use of oral
antivirals or interferon-alpha for CHB treatment; co-infection with
hepatitis D virus (HDV), hepatitis C virus (HCV), or HIV; non-
adherence to treatment; cirrhosis; hepatic decompensation; HCC
or any other malignancy; autoimmune hepatitis; illicit drug use;
solid organ transplantation; pregnancy; age <18 years.
All of the patients were followed-up periodically, and CHB
serology, biochemistry, and virology were investigated every 3 to
6 months. Compliance with therapy was questioned. The following
data were collected from the patient records and transferred to an
Excel ﬁle: age, gender, Ishak scores for pre-treatment liver biopsysamples (histological activity index (HAI) and ﬁbrosis),18 HBsAg,
HBeAg, and hepatitis B e antibody (anti-HBe) status, serum ALT,
aspartate aminotransferase (AST), and HBV-DNA levels before
treatment and at months 3, 6, 12, 18, and 24 of treatment, time to
ALT normalization, undetectable HBV-DNA levels, and HBeAg
seroconversion (in HBeAg-positive cases), and total duration of
follow-up on therapy. The data obtained were analysed and
compared for virological (undetectable HBV-DNA levels), bio-
chemical (ALT normalization), and serological (HBeAg seroconver-
sion in HBeAg-positive patients, HBsAg seroconversion) responses
to treatment with the two antiviral agents. Declines in serum HBV-
DNA levels from baseline to weeks 12, 24, and 48 were compared
for the two groups of patients to evaluate treatment efﬁcacy. For
HCC screening, all patients underwent abdominal ultrasonography
every 6 months.
2.2. Deﬁnitions
A complete virological response was deﬁned as complete viral
suppression, shown by serum HBV-DNA levels <20 IU/ml (<100
copies/ml) at week 48.1 A partial virological response was deﬁned
as a decrease in HBV-DNA of more than 1 log10 IU/ml but
detectable serum HBV-DNA levels by PCR at 12 months of
therapy in compliant patients.1 Virological breakthrough was
deﬁned as a >1 log10 IU/ml increase in serum HBV-DNA levels from
nadir on two consecutive measurements.1
Serological response was deﬁned as HBeAg seroconversion
(HBeAg loss and anti-HBe development) in HBeAg-positive cases.1
Biochemical response was deﬁned as ALT normalization (decline in
ALT levels to less than the upper limit of normal) in patients with
pre-treatment elevated ALT levels.1
Patients were considered compliant with therapy if they took
their drugs once daily, regularly, without an interruption.
With regard to adverse effects, any symptom or sign, or
abnormal clinical or laboratory ﬁnding that resolved after
discontinuation of the drug was considered a drug-related adverse
effect. An increase in serum creatinine level exceeding the upper
limit of normal was considered a drug-related renal adverse effect.
2.3. Virological tests
HBsAg, HBeAg, and anti-HBe were tested with an ELISA
(Architect System; Abbott Laboratories, North Chicago, IL, USA).
Levels of serum HBV-DNA were tested with a PCR assay (TaqMan
HBV Assay; Roche Diagnostics); the lower limit of HBV-DNA
quantiﬁcation was 20 IU/ml.
2.4. Ethical approval
This study was approved by the local ethics committee
(Institutional Review Board of Istanbul Medipol University,
Turkey).
2.5. Statistical analyses
SPSS 17.0 software (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses. Categorical variables were deﬁned as the
proportion (%) and were compared by Chi-square test or Fisher’s
exact test. Continuous variables were deﬁned as the mean 
standard deviation (SD) or median (range) and were tested with the
Student t-test or Mann–Whitney U-test, as appropriate. After the
rates of periodic (3–6-month intervals) log decline in serum HBV-
DNA levels of patients in the two groups were calculated, an
independent samples t-test was used to test the difference.
Cumulative rates of complete viral suppression were analysed
by Kaplan–Meier method and were compared by log rank test.
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analysis was used to identify the variables/factors determining the
virological response. A p-value of <0.05 was considered to be
statistically signiﬁcant.
3. Results
The data of a total 210 patients with CHB who were prescribed
either TDF or ETV were recorded. Among these patients, 195 (72%
male, mean age 43  12 years) were eligible for inclusion in the
study. They were followed-up for a mean duration of 30.2  15.7
(range 12–72) months. Ninety (46%) patients received TDF (mean
treatment duration 27.2  15.4 months) and 105 (54%) patients
received ETV (mean treatment duration 33.0  15.4 months).
Twenty-nine (32%) patients in the TDF group and 36 (34%)
patients in the ETV group were HBeAg-positive. Patients in the two
treatment groups were similar in terms of baseline parameters:
age (p = 0.65), gender (p = 0.06), ratios of HBeAg positivity
(p = 0.76), pre-treatment mean ALT (p = 0.55), and serum HBV-
DNA levels (p = 0.42) (Table 1).
A pre-treatment liver biopsy was performed in 92% of patients
prescribed TDF and 90% of patients prescribed ETV. Pre-treatment
liver biopsy scores differed between the two groups (HAI, p = 0.01;
ﬁbrosis, p = 0.03); mean HAI scores were 7.6  2.7 and 8.6  2.8 and
mean ﬁbrosis scores were 2.5  1.4 and 2.3  1.0 for the TDF and ETV
groups, respectively.
HBeAg clearance (24% in TDF vs. 44% in ETV) and seroconver-
sion rates (24% in TDF vs. 39% in ETV) in HBeAg-positive patients in
the two groups did not differ signiﬁcantly (p = 0.1 and p = 0.2),
although the rates were relatively higher in the ETV group. The
mean time to achieve undetectable serum HBV-DNA levels in the
TDF group was 11.5  8.9 months, while it was 12.9  10.8 months
in the ETV group; the difference was not signiﬁcant (p = 0. 32).
The mean time to ALT normalization (p = 0.1) and rates of ALT
normalization at 3, 6, 12, 18, and 24 months were similar in the two
groups (Table 2).
When the decline from pre-treatment serum HBV-DNA levels at
months 3, 6, 12, 18, and 24 were compared, there was no
statistically signiﬁcant difference between the TDF and ETV groupsTable 1
Comparison of baseline demographic variables, laboratory and histological
tenofovir (TDF) or entecavir (ETV) therapya
Characteristics TDF (n = 90)
Age, years 43.3  12.9
Gender, male 59.0 
Treatment duration, months 27.2  15.4
HBeAg positivity 29.0 (32.2
Pre-treatment HBV-DNA, 103 IU/ml 191 613  1
Pre-treatment ALT, IU/l 116.7  92.6
Elevated ALT before therapy 80.0 (89.0
Liver biopsy done 83.0 (92.0
Baseline HAI (Ishak) 7.6  2.7 
Baseline ﬁbrosis (Ishak) 2.5  1.4 
HBeAg loss 7.0 (24.0
HBeAg seroconversion 7.0 (24.0
Time to HBeAg seroconversion, months 12.3  5.6 
ALT normalization 88.0 (97.8
Time to ALT normalization, months 5.1  3.6 
Undetectable HBV-DNA 77.0 (85.6
Time to undetectable HBV-DNA, months 11.5  8.9 
Virological breakthrough 0 
HBsAg seroclearance 1.0 (1.1%
HCC development 0 
Decompensation 0 
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotr
antigen; HCC, hepatocellular carcinoma.
a Results are given as the mean  standard deviation, or n (%).at months 6, 12, 18, and 24 (p > 0.05). However, TDF induced a
signiﬁcantly greater reduction in serum HBV-DNA levels at month
3 (p = 0.047). As most of the patients (80%) achieved a virological
response by 24 months of antiviral therapy, we did not further
compare log declines thereafter.
When the rates of cumulative complete viral suppression
(undetectable serum HBV-DNA levels) at months 3, 6, 12, 18, and
24 were compared between the two groups, they were signiﬁ-
cantly higher at month 12 (p = 0.02) and month 18 (p = 0.03) in
patients on TDF therapy (at months 12 and 18, TDF induced a
signiﬁcantly increased rate of undetectable serum HBV-DNA levels
compared to ETV; p = 0.02 and p = 0.03, respectively) (Figure 1).
Seven (7%) patients who were on ETV therapy developed
virological breakthrough, but none of the patients in the TDF group
did (p = 0.01). These seven patients claimed that they had adhered
to therapy well, but a resistance analysis could not be performed at
that time. They were switched to TDF therapy. The changes in ALT
and HBV-DNA levels over time in the seven patients with
virological breakthrough are shown in Tables 3 and 4, respectively.
Only one patient in each group had HBsAg clearance. None of
the patients in any group developed hepatic decompensation or
HCC during the entire treatment period. On Cox regression
analysis, none of the baseline parameters was found to be a
signiﬁcant predictor of the virological response (Table 5). Cumu-
lative rates of virological, biochemical, and serological response
(HBeAg loss and seroconversion) over time are illustrated in
Figures 2–4.
No serious adverse effects such as lactic acidosis, severe liver
problems, or increase in serum creatinine levels were seen in any of
the patients in either treatment group. No adverse effects leading
to discontinuation of therapy occurred during the whole treatment
period. Two patients on ETV therapy experienced nausea and
abdominal discomfort. One patient receiving ETV complained of
fatigue and dizziness that disappeared after a few days. Three
patients receiving TDF experienced nausea, one of them also had
diarrhoea that resolved with symptomatic therapy. Two patients
on TDF therapy developed hypophosphatemia (serum phosphate
level <2.5 mg/dl), but they had no related symptoms such as
fatigue or muscle weakness. Two patients receiving ETV therapy parameters, and treatment responses of patients who received either
 ETV (n = 105) p-Value
 42.0  11.2 0.7
82.0 (78.1%) 0.06
 33.0  15.4 0.01
%) 36.0 (34.3%) 0.8
98.6 220 199  101.3 0.4
 120.0  96.6 0.6
%) 94.0 (90.0%) 0.9
%) 94.0 (90.0%) 0.8
8.6  2.8 0.01
2.3  1.0 0.03
%) 16.0 (44.0%) 0.1
%) 14.0 (39.0%) 0.2
12.3  5.8 0.9
%) 104.0 (99.0%) 0.1
6.3  5.3 0.08
%) 90.0 (85.7%) 0.9
12.9  10.8 0. 3
7.0 (6.7%) 0.01
) 1.0 (0.95%)
0
0
ansferase; HAI, histological activity index; HBsAg, hepatitis B surface
Table 2
Comparison of the cumulative virological responses and ALT normalization at 3, 6,
12, 18, and 24 months in patients with chronic hepatitis B who were prescribed
either tenofovir (TDF) or entecavir (ETV)
TDF (n = 90),
n (%)
ETV (n = 105),
n (%)
Total p-Value
3 months
ALT normalization 36 (40.0) 29 (27.6) 65 (33.3) 0.07
Undetectable HBV-DNA 5 (5.6) 2 (1.9) 7 (3.6) 0.2
6 months
ALT normalization 64 (71.1) 80 (76.2) 144 (73.8) 0.4
Undetectable HBV-DNA 21 (23.6) 19 (18.1) 40 (20.6) 0.4
12 months
ALT normalization 78 (97.5) 93 (93.9) 171 (95.5) 0.3
Undetectable HBV-DNA 62 (74.7) 59 (58.4) 121 (65.8) 0.02
18 months
ALT normalization 61 (98.4) 85 (96.6) 146 (97.3) 0.5
Undetectable HBV-DNA 53 (82.8) 60 (67.4) 113 (73.9) 0.03
24 months
ALT normalization 49 (98.0) 69 (98.6) 118 (98.3) 0.8
Undetectable HBV-DNA 45 (86.5) 53 (74.6) 98 (79.7) 0.1
ALT, alanine aminotransferase; HBV, hepatitis B virus.
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been obtained (one of them at the end of 2 years, the other at the
end of 30 months). One female patient in the TDF group
discontinued therapy for a period of 13 months as she planned
a pregnancy and conceived a baby. No hepatic ﬂare was observed
during the off-treatment period.3 mo 6 mo 12 mo 18 mo 24 mo
TDF 5.6 23. 6 74. 7 82. 8 86. 5
ETV 1.9 18. 1 58. 4 67. 4 74. 6
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Figure 1. (a) Cumulative rates of virological response over time in patients with chronic he
virological response at 3, 6, 12, 18, and 24 months, the p-values are 0.047, 0.68, 0.53, 0
months) in patients with chronic hepatitis B who received tenofovir (TDF) or entecavir (E
values are 0.07, 0.65, 0.43, 0.58, and 0.73, respectively.
Table 3
The course of ALT levels in seven patients on entecavir therapy with virological breakt
Patient Baseline
ALT, IU/l
ALT
normalization,
month
Virological
breakthrough,
month
ALT, IU/l
3 months 6 months 9
1 92 12 18b 85 60 5
2 120 6 24b 67 48 3
3 69 6 24b 62 33 3
4 89 8 36b NA 54 4
5 64 6 18b 54 43 4
6 108 3 18b 47 37 3
7 140 6 18b 82 41 N
ALT, alanine aminotransferase; NA, not available.
a ALT normal range: 0–50 IU/l.
b Switch to tenofovir disoproxil fumarate therapy.4. Discussion
The risk of developing cirrhosis and HCC is directly proportional
to the viral load in patients with CHB.2,3 Sustained suppression of
serum HBV-DNA levels is one of the therapeutic goals in patients
with CHB and prevents the progression of liver disease and
development of complications.19,20 The development of resistance
is a signiﬁcant problem with lamivudine, adefovir, and telbivudine
therapies.7–9 ETV and TDF are highly potent and safe NAs with
genetic barriers to resistance, and these drugs are recommended in
the ﬁrst-line treatment of CHB in current guidelines.1,11 In the
present study, the two drugs induced similar virological (mean
time to achieve undetectable HBV-DNA levels and rates of
achieving no HBV-DNA by PCR in serum), biochemical (mean
time to ALT normalization and rates of ALT normalization at 3, 6,
12, 18, and 24 months), and serological (HBeAg clearance and
seroconversion rates in HBeAg-positive patients, rates of HBsAg
clearance in the two groups) responses in patients with CHB.
Cumulative complete viral suppression was signiﬁcantly higher at
months 12 and 18 in patients on TDF therapy, but not different at
other time intervals during treatment with either drug. While 7% of
the patients on ETV therapy had virological breakthrough, none of
the patients on TDF therapy did.
In Bayesian mixed comparisons for the meta-analysis of relative
efﬁcacies of CHB treatments conducted by Woo et al., TDF was
reported to be the most effective at inducing virological,
biochemical, and serological responses in HBeAg-positive patients;
ETV ranked second. In HBeAg-negative patients, TDF was the most0.0000
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patitis B who received tenofovir (TDF) or entecavir (ETV). For the comparisons of the
.57, and 0.67, respectively. (b) Decline in serum HBV-DNA levels over time (3–24
TV). For the comparisons of HBV-DNA decline at 3, 6, 12, 18, and 24 months, the p-
hrougha
 months 12 months 18 months 24 months 30 months 36 months
7 32 67b 45 42
8 NA 26 96b 40
6 28 38 66b 37
2 40 NA 39 42 87b
6 42 79b 37 38 29
4 38 64b 31
A 42 85b 35 33 37
Table 4
The course of viremia in seven patients on entecavir therapy with virological breakthrough
Patient Baseline
HBV-DNA,
IU/ml
Undetectable
HBV-DNA,
month
Virological
breakthrough,
month
HBV-DNA, IU/l
3 months 6 months 12 months 18 months 24 months 30 months 36 months
1 17  106 12 18a 772  103 10.3  103 - 815a -
2 110  106 12 24a NA 2  106 - - 11 700a 5930 -
3 487  103 6 24a 48  103 - - - 6850a
4 1.627  106 6 36a 121  103 - - - - - 480 000a
5 1.826  106 6 18a 594 - - 3600a - -
6 95  106 12 18a 112  103 7090 - 4200a -
7 37.72  106 10 18a 5930 1300 - 6577a - - NA
HBV, hepatitis B virus; NA, not available.
a Switch to tenofovir disoproxil fumarate therapy.
Table 5
Results of the Cox regression analysis to determine independent variables
predictive of the virological response
Characteristics HR (95% CI) p-Value
Age 1.00 (0.99–1.02) 0.39
Gender 0.78 (0.60–1.1) 0.53
HBeAg positivity 1.56 (0.58–4.16) 0.38
Anti-HBe positivity 2.02 (0.75–5.42) 0.16
Pre-treatment HBV-DNA 1 (1–1) 0.86
Pre-treatment ALT 1.00 (0.9–1.01) 0.77
Baseline HAI (Ishak) 1.00 (0.95–1.07) 0.58
Baseline ﬁbrosis (Ishak) 1.10 (0.95–1.3) 0.77
Therapy with TDF vs. ETV 1.10 (0.79–1.5) 0.52
HR, hazard ratio; CI, conﬁdence interval; HBeAg, hepatitis B e antigen; anti-HBe,
hepatitis B e antibody; HBV, hepatitis B virus; ALT, alanine aminotransferase; HAI,
histological activity index; TDF, tenofovir; ETV, entecavir.
Figure 2. Cumulative probabilities of a virological response to tenofovir (TDF) and
entecavir (ETV) therapy (p = 0.72).
Figure 3. Cumulative probabilities of a biochemical response to tenofovir (TDF) and
entecavir (ETV) therapy (p = 0.86).
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ranked second for biochemical response.21 Dakin et al. reported
that TDF was signiﬁcantly superior to ETV regarding virological
response, but comparable to ETV regarding HBeAg seroconversion
after 1 year of therapy.22 Both drugs were reported to be effective
and well tolerated in compensated and decompensated cirrhotic
patients.23
In our study, HBeAg clearance and seroconversion rates in
HBeAg-positive patients were relatively higher in the ETV group,but did not differ signiﬁcantly from the TDF group. Myung et al.
reported the cumulative rates of HBeAg loss at 12 to 72 weeks of
ETV therapy as 10.6% to 34.5%; and 3.5% to 13.2% for HBeAg
seroconversion.24 TDF therapy resulted in HBeAg loss in 24% of
patients in another study.25 In the study by Ceylan et al., HBeAg
status did not predict the virological response rate, similar to the
ﬁnding of our study.15 Chang et al. reported a lower rate of HBeAg
seroconversion at year 5.26 HBeAg seroconversion occurred in only
one of 29 patients in the ETV group, but none of 65 patients in the
TDF group in another study.16
The mean time to ALT normalization and rates of ALT
normalization at 3, 6, 12, 18, and 24 months were similar in the
two groups in the present study. Guzelbulut et al. reported that a
similar proportion of patients achieved ALT normalization on ETV
or TDF therapy.17 Chang et al. reported that ALT normalization in
patients on ETV therapy was 80% at year 5.26 Cumulative rates for
biochemical response at 12, 24, 48, and 72 weeks of therapy with
ETV were reported to be 40.0%, 66.2%, 84.5%, and 92.7%,
respectively.24
The mean time to achieve undetectable HBV-DNA levels and
rates of achieving negative HBV-DNA levels by PCR in serum in
both groups were not signiﬁcantly different. This is consistent
with the results of the studies conducted by Guzelbulut et al.17
and Dogan et al.16 Chang et al. reported that the rate of
undetectable serum HBV-DNA levels at year 5 was 94% in
ETV-treated patients.26
Figure 4. (a) Cumulative HBeAg clearance over time in response to tenofovir (TDF) and entecavir (ETV) therapy (p = 0.63). (b) Cumulative HBeAg seroconversion over time in
response to tenofovir (TDF) and entecavir (ETV) therapy (p = 0.56).
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levels at months 6, 9, 12, 18, and 24 were not signiﬁcantly different
between the TDF and ETV groups, but TDF induced a signiﬁcantly
greater reduction in serum HBV-DNA level at month 3. In contrast,
in a recently published study, a greater decline in serum HBV-DNA
levels at month 3 occurred with ETV therapy; however, the rates of
decline in HBV-DNA levels at other months did not differ
signiﬁcantly, similar to our results.15 Moreover, Guzelbulut et al.
reported similar rates of decline in serum HBV-DNA levels with
both drugs after 48 months of therapy.17
TDF induced a signiﬁcantly more increased rate of undetectable
HBV-DNA levels at months 12 and 18 compared to ETV, but the
rates of undetectable HBV-DNA levels at months 3, 6, 12, 18, and
24 were similar. Myung et al. reported higher cumulative rates of
virological response at 3, 6, 12, and 18 months in patients on ETV
therapy than in patients on TDF therapy.24 The difference was due
to the threshold of the serum HBV-DNA level for virological
response, which was set at <2000 copies/ml (approximately
400 IU/ml). In our study, a ‘complete virological response’ was
deﬁned as serum HBV-DNA levels <20 IU/ml (<100 copies/ml).
The overall cumulative proportion of patients achieving serum
HBV-DNA levels <400 copies/ml was 79% after a mean treatment
duration of nearly 2 years in another study including CHB patients
with prior treatment failure who were subsequently switched to
TDF therapy.25 Dogan et al. reported that either TDF or ETV therapy
resulted in suppression of HBV-DNA levels in 71.3% of patients at
the end of 48 weeks (66% in the present study). There was no
statistical difference in the induction of undetectable levels of
HBV-DNA between the ETV and TDF groups.16 Ceylan et al.
reported that TDF-treated patients had a better virological
response than ETV-treated ones. ETV was more effective in
reducing serum HBV-DNA levels at month 3 of antiviral therapy.15
Seven (7%) patients on ETV therapy developed virological
breakthrough, but none of the patients in the TDF group did.
While no viral breakthrough was observed in a study that
included 114 naive CHB patients on ETV therapy,27 in another
study involving 258 ETV-treated patients, only ﬁve developed
ETV resistance, which is less than in our study.28 In another
study which evaluated the long-term efﬁcacy of TDF in
131 patients, virological breakthrough was not observed.25 In
the study by Chang et al., ETV resistance emerged in only one
patient during 5 years of follow-up, therefore they suggestedextended long-term therapy with ETV through 5 years in
HBeAg-positive CHB.26
Only one patient in each group developed HBsAg clearance. van
Bommel et al. reported HBsAg loss in 3% of 131 TDF-treated CHB
patients with prior resistance to other antiviral drugs.25 Chang
et al. reported that the rate of HBsAg loss was 1.4%.26While none of
the baseline parameters of the patients were signiﬁcant predictors
of the virological response in the present study, HBeAg seronega-
tivity and a low serum HBV-DNA level at baseline were reported to
be signiﬁcant predictors of the virological response by Myung
et al.24
The main limitation of our study is its retrospective design. Pre-
treatment liver biopsy scores were available for most of the
patients and they were different in the two groups, as the study
design was retrospective. It is very difﬁcult to convince patients to
have a control biopsy performed at the end of treatment. Therefore,
we could not compare the histological improvement in response to
therapy to the two drugs. Moreover, the presumably ETV-resistant
strains were not sequenced because the patients’ health insurance
companies would not pay for this and we could not obtain funding
for this purpose. Nevertheless, we involved quite a large number of
patients in the study. We also looked for the predictors of a
response with the parameters available, but none of them was
signiﬁcant.
In conclusion, rates of HBeAg seroconversion in HBeAg-positive
patients, ALT normalization, and serum HBV-DNA clearance were
not signiﬁcantly different in the two treatment groups. Moreover,
the mean time to achieve undetectable serum HBV-DNA levels and
ALT normalization were similar. Both drugs resulted in signiﬁcant
viral suppression, but the HBsAg clearance rate was very low with
both drugs. Seven percent of patients on ETV therapy experienced
virological breakthrough, while none of the patients on TDF
therapy did. The two drugs induced comparable virological,
biochemical, and serological responses in CHB patients.
Funding: None.
Conﬂict of interest: None to declare.
References
1. European Association for the Study of the Liver. EASL clinical practice guide-
lines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:
167–85.
A. Batirel et al. / International Journal of Infectious Diseases 28 (2014) 153–159 1592. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on
the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–86.
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular
carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA 2006;295:65–73.
4. Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A. Speciﬁc
mutations of basal core promoter are associated with chronic liver disease in
hepatitis B virus subgenotype D1 prevalent in Turkey. Microbiol Immunol
2013;57:122–9.
5. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, et al. Response-
guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B
using serum hepatitis B surface antigen levels. Hepatology 2013;58:872–80.
6. Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-alpha(2a) in clinical
practice: how to manage patients suffering from side effects. Expert Opin Drug
Saf 2011;10:429–35.
7. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A
treatment algorithm for the management of chronic hepatitis B virus infection
in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936–62.
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,
et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic
hepatitis B for up to 5 years. Gastroenterology 2006;131:1743–51.
9. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial
results: telbivudine Is superior to lamivudine in patients with chronic hepatitis
B. Gastroenterology 2009;136:486–95.
10. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the
treatment of chronic hepatitis B. J Antimicrob Chemother 2011;66:2715–25.
11. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology
2009;50:661–2.
12. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Paciﬁc
consensus statement on the management of chronic hepatitis B: a 2008 update.
Hepatol Int 2008;2:263–83.
13. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schwalder J, et al. No
resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy
in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763–73.
14. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir
resistance is rare in nucleoside naive patients with hepatitis B. Hepatology
2006;44:1656–65.
15. Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, et al.
Comparison of tenofovir and entecavir in patients with chronic HBV infection.
Eur Rev Med Pharmacol Sci 2013;17:2467–73.16. Dogan UB, Kara B, Gumurdulu Y, Soylu A, Akin MS. Comparison of the efﬁcacy of
tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with
chronic hepatitis B. Turk J Gastroenterol 2012;23:247–52.
17. Guzelbulut F, Ovunc AO, Oetinkaya ZA, Senates E, Go¨kden Y, Salturk AG, et al.
Comparison of the efﬁcacy of entecavir and tenofovir in chronic hepatitis B.
Hepatogastroenterology 2012;59:477–80.
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological
grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
19. Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int
2013;33(Suppl 1):111–5.
20. Abu-Amara M, Feld JJ. Does antiviral therapy for chronic hepatitis B reduce the
risk of hepatocellular carcinoma? Semin Liver Dis 2013;33:157–66.
21. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong D.F K.. et al.
Tenofovir and entecavir are the most effective antiviral agents for chronic
hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology
2010;139:1218–29.
22. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evalu-
ating the relative efﬁcacy of nucleos(t)ides for treatment of nucleos(t)ide-naive
patients with chronic hepatitis B. Value Health 2010;13:934–45.
23. Miquel M, Nunez O, Trapero-Marugan M, Diaz-Sanchez A, Jimenez M, Arenas J,
et al. Efﬁcacy and safety of entecavir and/or tenofovir in hepatitis B compen-
sated and decompensated cirrhotic patients in clinical practice. Ann Hepatol
2013;12:205–12.
24. Myung HJ, Jeong SH, Kim JW, Kim HS, Jang JH, Lee DH, et al. [Efﬁcacy
and predictors of the virologic response to entecavir therapy in nucleo-
side-naive patients with chronic hepatitis B]. Korean J Hepatol
2010;16:57–65.
25. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P,
et al. Long-term efﬁcacy of tenofovir monotherapy for hepatitis B virus-mono-
infected patients after failure of nucleoside/nucleotide analogues. Hepatology
2010;51:73–80.
26. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir
treatment for up to 5 years in patients with hepatitis B e antigen-positive
chronic hepatitis B. Hepatology 2010;51:422–30.
27. Lee MH, Lim SG, Jeon SJ, Kang CJ, Cho YJ, Kim SS, et al. [Clinical efﬁcacy of
entecavir therapy and factors associated with treatment response in naive
chronic hepatitis B patients]. Korean J Hepatol 2009;15:446–53.
28. Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, et al. [Results of 3 years of
continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B
patients]. Zhonghua Gan Zang Bing Za Zhi 2009;17:881–6.
